Message from the CEO
I am pleased to report that the trends mentioned in the last Newsletter continue to improve. We can now boast successful delivery of aptamers to a range of small and large molecule targets for customers in academia, biotech and big Pharma. We are also moving towards integration of aptamers into devices and […]
10 November 2016
We are thrilled to announce that our CTO Dr David Bunka has been invited to speak at our local Venture Fest here in Yorkshire. The conference will be held on Wednesday 16th November 2016 at York Racecourse.
Organised by Made It York, Venturefest Yorkshire is a one day festival with a clear remit to […]
06 July 2016
We were thrilled to be invited by Dr Beat Loeffler to represent our aptamer technology at CLINAM, European Foundation for Clinical Nanomedicine 2016.
In the previous eight years, CLINAM summit grew to the largest in its field with 12 presenting Noble Laureates and more than 500 participants from academia, industry, regulatory authorities and policy […]
15 April 2016
Update from Chief Technical Officer Dr David Bunka, Aptamers 2016
It was great to be invited back to the International Society of Aptamers, Aptamers 2016 for the third time. The annual conference brings together academia, and industrial aptamer preachers and solution providers. It addresses therapeutic, diagnostic, analytical and basic research applications aptamers.
As this is […]
4 April 2016
It is the third Oxford symposium on aptamers and we are delighted to announce that Dr David Bunka has been invited as a featured speaker for the third year running.
The conference is designed to bring together academic and industrial aptamer researchers and solution providers. The conference will address therapeutic, diagnostic and research based […]
19 February 2016
We are delighted to announce that our CTO Dr David Bunka has been invited to speak at SMIs 7tH Annual conference on RNA Therapeutics on the 16th February 2016.
The 2016 RNA Therapeutics conference will hone in on some key developments currently shaping the industry, and putting the spotlight on messenger RNA-based Therapeutics.
It will […]
